Navigation Links
Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
Date:11/6/2008

Atherotech to add new apoA1 measurement and apoB:apoA1 ratio to its comprehensive cholesterol test, further identifying patients at risk of

heart disease

BIRMINGHAM, Ala., Nov. 6 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP(R) Cholesterol Test in booth No. 2918 at the American Heart Association Scientific Sessions 2008. The annual meeting takes place Nov. 8-12 at the Ernest N. Morial Convention Center in New Orleans.

Atherotech representatives will be available to discuss the VAP Cholesterol Test during regular exhibit hours on October 9, 10 and 11 in booth No. 2918, and the VAP Test will be provided via blood draw to qualified attendees. Test results will be returned via mail after the conference.

The VAP (vertical auto profile) Test is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters - LDL, non-HDL and apoB - considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology.

"Detailed risk profiling through advanced lipid testing is changing the way we evaluate and manage heart disease risk," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The VAP Test is affordable, widely covered by insurance and will play an increasingly important role in heart attack and stroke prevention."

The VAP Test reports all 15 lipoprotein measurements with a single test, and unlike other lipid profiles, it directly measures LDL and HDL and includes Lp(a) and apoB as part of its standard test. Atherotech has announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early 2009. ApoA1 is the main component of protective HDL cholesterol and studies have shown that the apoB:apoA1 ratio may correlate better with increased risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL ratio.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test.

The VAP Cholesterol Test has been shown to identify significantly more patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test). Risks of both heart disease and diabetes can be reduced with the right preventive treatments, which is why more accurate diagnosis is critical.

The VAP Test is available nationwide. For more information call 877.901.8510 or visit http://www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP(R) technology, which directly measures the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for LDL measurement and the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Cholesterol Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
2. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
3. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
6. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
11. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, Inc. ... on its oral peptide drug candidates, PTG-100 and ... the European Crohn,s and Colitis Organization (ECCO).  The ... Barcelona, Spain from February 15 – ... preclinical data on Protagonist drug candidates PTG-100 and ...
(Date:2/16/2017)... Ann Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... between 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 ... hosted by a MichBio member organization. They provide an opportunity to interact with peers, ...
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):